Qiagen Q2 FY26 adjusted diluted EPS rises to $0.62; net sales hold at $535 million
QGEN•Growth pillars and outlook
Growth pillars rose about 5%, while QuantiFERON edged up 1% on lower U.S. immigration testing demand.
Qiagen reaffirmed its 2026 outlook for net sales growth of about 1%-2% and non-GAAP adjusted diluted EPS of at least USD 2.43.
Quarterly results hold sales flat
Qiagen posted Q2 net sales flat year on year at USD 535 million.
- GAAP diluted EPS held at USD 0.50.
- Non-GAAP adjusted diluted EPS was USD 0.62.
- Non-GAAP adjusted operating income margin was 29.4% as profitability stayed elevated.
